SCHEMBL30196046

SCHEMBL30196046

CC(=O)Nc1ccc(-c2ccc3[nH]cc(NC(=O)Nc4ccc(C(F)(F)F)cc4)c3c2)cc1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 10/20 0.65
▸ EPHX2 P34913 1/20 0.48
▸ IDO1 P14902 1/20 0.47
▸ TDO2 P48775 1/20 0.47
▸ KIF11 P52732 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MAPT P10636 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ IDH1 O75874 1/20 0.46
▸ GOT1 P17174 1/20 0.45
▸ PSEN1 P49768 1/20 0.43
▸ PSEN2 P49810 1/20 0.43
▸ APH1B Q8WW43 1/20 0.43
▸ NCSTN Q92542 1/20 0.43
▸ APH1A Q96BI3 1/20 0.43
▸ PSENEN Q9NZ42 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23208067 1.00 STING1 (0.65) STING1EPHX2IDO1TDO2KIF11
SCHEMBL23208061 0.90 STING1 (0.64) STING1EPHX2KIF11MEN1KMT2A
SCHEMBL23167861 0.90 STING1 (0.73) STING1EPHX2MEN1KMT2AMAPT
SCHEMBL23207945 0.90 STING1 (0.66) STING1EPHX2KIF11MEN1KMT2A
SCHEMBL30196056 0.89 STING1 (0.62) STING1EPHX2MEN1KMT2AMAPT
SCHEMBL24835269 0.89 STING1 (0.62) STING1EPHX2MEN1KMT2AMAPT
SCHEMBL23207649 0.89 STING1 (0.65) STING1EPHX2MAPTIDH1GOT1
SCHEMBL24835270 0.89 STING1 (0.61) STING1EPHX2MEN1KMT2AMAPT
SCHEMBL23166575 0.89 STING1 (0.61) STING1EPHX2MEN1KMT2AMAPT
SCHEMBL23207905 0.88 STING1 (0.63) STING1EPHX2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 STING1 1/4885EPHX2 730/4885IDO1 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback